Abstract: Poster Presentations |

Patients with Obstructive Lung Disease Prefer Respimat® Soft Mist(TM) Inhaler to pMDI FREE TO VIEW

Richard V. Hodder, MD*; Wolfgang Schurmann, MD; Petra Moroni; Michael Barczok, MD
Author and Funding Information

University of Ottawa, Ottawa, ON, Canada


Chest. 2004;126(4_MeetingAbstracts):806S. doi:10.1378/chest.126.4_MeetingAbstracts.806S
Text Size: A A A
Published online


PURPOSE:  Respimat® Soft Mist(TM) Inhaler (SMI) is a novel, propellant-free device which produces a slow-moving, long-lasting aerosol that is easy to inhale and has excellent deposition efficiency. Satisfaction with and preference for Respimat® SMI was assessed in three randomised, open-label studies.

METHODS:  In study A (Canada; n=129; mean age 66.1), COPD patients received ipratropium bromide (IB; 20 or 40 ug) or placebo qid via Respimat® SMI for 6 months; in study B, (Germany; n=47; mean age 63.7) COPD patients received IB/fenoterol (10/25 or 20/50 ug) or placebo qid via Respimat® SMI for 12 weeks. In study C (Germany; n=245; mean age 55.3), COPD, asthma or mixed disease patients received, tid or qid, IB/fenoterol 20/50 ug via Respimat® SMI or 40/100 ug via pressurised metered dose inhaler (pMDI) for 7 weeks each in a crossover design. Questionnaires on device satisfaction, preference and willingness to continue were completed after each treatment period or at the end of the study.

RESULTS:  Most patients in studies A and B (94 and 85%, respectively) said they would prefer to use Respimat® SMI over their current inhaler. Willingness to continue using Respimat® SMI was high (A, 80%; B, 72%), as was overall satisfaction with Respimat® SMI, with 74% (A) and 64% (B) giving ratings of 9 or 10 (10 = “extremely satisfied”). Of the 201 patients in study C who completed an assessment of both devices and expressed a preference, 162 (81%) preferred Respimat® SMI (p<0.001). Preference was unaffected by age or co-existing conditions that might adversely affect inhaler handling. Willingness-to-continue scores were significantly higher for Respimat® SMI than pMDI (p<0.001). Mean scores for 13 of the 15 items in the satisfaction questionnaire were higher for Respimat® SMI.

CONCLUSION:  In these 3 studies, patients were highly satisfied with Respimat® SMI and the vast majority preferred this device to the pMDI.

CLINICAL IMPLICATIONS:  Adherence to inhaler therapy and thus disease control may be enhanced when patients are offered an inhaler device that they prefer over the pMDI.

DISCLOSURE:  R.V. Hodder, None.

Wednesday, October 27, 2004

12:30 PM - 2:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543